EXOMIND™ – a next-generation transcranial magnetic stimulation (TMS) device designed to support mental wellness, improve cognitive function and reduce symptoms of anxiety – all without medication or downtime.
Backed by decades of neuroscience research, TMS has long been used in psychiatry clinics for the treatment of mental health conditions – and it forms the core technology behind EXOMIND™. By using magnetic fields to stimulate nerve cells in the brain, TMS helps improve communication between them. EXOMIND™ delivers this powerful brain stimulation therapy in a safe, non-invasive and time-efficient way, offering more people a practical and accessible way of supporting their mental wellbeing.
How does EXOMIND™ work?
Think of EXOMIND™ as a workout for the mind. It uses targeted electromagnetic pulses to stimulate the dorsolateral prefrontal cortex – a region in the brain involved in emotional regulation, decision-making and cognitive function. This stimulation improves how neurons (the brain’s message-sending cells) communicate, strengthens neuroplasticity (the brain’s ability to adapt and rewire) and triggers the release of key neurotransmitters like serotonin and dopamine – the natural brain chemicals that help stabilise mood and emotions.
“Conditions like stress, anxiety and emotional overwhelm are becoming increasingly common and many people want an alternative to medication to feel more balanced and in control of their mind and emotions. EXOMIND™ supports the mind’s natural ability to reset and restore emotional balance. It’s an excellent device that is helping my patients who feel overwhelmed, anxious or mentally fatigued to feel calmer and more focused. EXOMIND™ is the next evolution in holistic wellness, where mental wellbeing is given the same attention as skin and physical health.” – Dr Sherina Balaratnam of the S-Thetics Clinic.
Evidence-based and clinically supported
TMS is backed by over 20 years of clinical research. In-house studies conducted by BTL with more than 200 patients discovered that:
- 90% reported improved mental wellbeing
- 74% felt less stressed
- 77% experienced better mood and energy
- 71% reported improved sleep onset.
Further independent clinical studies on EXOMIND™ are underway, with results expected to be published in 2025.
FURTHER INFORMATION
